An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
Multiple Myeloma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 312 (final count)
- Started
- Dec 13, 2018
- Main results expected
- Jan 15, 2026
- Fully finished
- Jan 15, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall response rate (ORR)- Cohort 1
Measured over: Up to approximately 5 years (Participants will transition to the long term follow-up (LTFU) study after a minimum of 12 months post-infusion for Cohorts 1, 2a, 2b, and 2c; and after a minimum of 6 months post-infusion for Cohort 1b, at their next visit)
Complete response (CR) rate - Cohort 1b, 2a, 2b, 2c, and Cohort 3
Measured over: Up to approximately 5 years (Participants will transition to the LTFU study after a minimum of 12 months post-infusion for Cohorts 1, 2a, 2b, and 2c; and after a minimum of 6 months post-infusion for Cohort 1b, at their next visit)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03601078 · record last updated 2026-03-04 · checked 2026-11-09 15:47 UTC